Your browser doesn't support javascript.
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.
Rice, Adrian; Verma, Mohit; Shin, Annie; Zakin, Lise; Sieling, Peter; Tanaka, Shiho; Balint, Joseph; Dinkins, Kyle; Adisetiyo, Helty; Morimoto, Brett; Higashide, Wendy; Anders Olson, C; Mody, Shivani; Spilman, Patricia; Gabitzsch, Elizabeth; Safrit, Jeffrey T; Rabizadeh, Shahrooz; Niazi, Kayvan; Soon-Shiong, Patrick.
  • Rice A; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Verma M; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Shin A; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Zakin L; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Sieling P; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Tanaka S; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Balint J; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Dinkins K; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Adisetiyo H; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Morimoto B; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Higashide W; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Anders Olson C; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Mody S; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Spilman P; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Gabitzsch E; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Safrit JT; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Rabizadeh S; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Niazi K; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA.
  • Soon-Shiong P; ImmunityBio, Inc., 9920 Jefferson Blvd, Culver City, CA, 90232, USA. Patrick@NantWorks.com.
Sci Rep ; 11(1): 14917, 2021 07 21.
Article in English | MEDLINE | ID: covidwho-1320238
ABSTRACT
We have developed a COVID-19 vaccine, hAd5 S-Fusion + N-ETSD, that expresses SARS-CoV-2 spike (S) and nucleocapsid (N) proteins with modifications to increase immune responses delivered using a human adenovirus serotype 5 (hAd5) platform. Here, we demonstrate subcutaneous (SC) prime and SC boost vaccination of CD-1 mice with this dual-antigen vaccine elicits T-helper cell 1 (Th1) biased T-cell and humoral responses to both S and N that are greater than those seen with hAd5 S wild type delivering only unmodified S. We then compared SC to intranasal (IN) prime vaccination with SC or IN boosts and show that an IN prime with an IN boost is as effective at generating Th1 biased humoral responses as the other combinations tested, but an SC prime with an IN or SC boost elicits greater T cell responses. Finally, we used a combined SC plus IN (SC + IN) prime with or without a boost and found the SC + IN prime alone to be as effective in generating humoral and T-cell responses as the SC + IN prime with a boost. The finding that SC + IN prime-only delivery has the potential to provide broad immunity-including mucosal immunity-against SARS-CoV-2 supports further testing of this vaccine and delivery approach in animal models of viral challenge.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-94364-5

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-94364-5